10-Q quarterly report · filed Nov 3, 2026

Spyre Therapeutics, Inc. (SYRE) Q3 2026 10-Q Quarterly Report

Short answer

Spyre Therapeutics, Inc. (SYRE) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$96M
−759.5% YoY · −165.5% QoQ
EPS (diluted)
−$0.95
−533.3% YoY · −171.4% QoQ

Source: XBRL data from the Spyre Therapeutics, Inc. (SYRE) Q3 2026 10-Q on SEC EDGAR. USD.

Spyre Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no commercial product sales
  • Net loss $96.1M vs $11.2M YoY, operating loss $105.7M vs $56.9M
  • Gastroenterology largest R&D program at $38.3M, dermatology fastest-growing at $11.9M vs $0
  • Operating cash outflow $204.7M, financing inflow $446.9M, including $435.2M April offering proceeds
  • Funding outlook: resources expected through second half of 2029, additional financing needed for further development

Risk Factors

  • Newly added risk: BIOSECURE Act could force CMO changes, triggered by FY 2026 National Defense Authorization Act restrictions on Chinese biotechnology companies
  • Most materially updated risk: SPY072 rheumatic-disease program discontinued in November 2026 after Phase 2 development
  • Regulatory risk: FDA disruptions from federal layoffs, leadership turnover, budget pressure, and potential shutdowns could delay submissions
  • Operational risk: WuXi Biologics remains a China-based CMO, creating potential manufacturing-transfer delays if designated a biotechnology company of concern
  • Financial risk: $1.1 billion cash, cash equivalents, and marketable securities as of September 30, 2026, but continued capital raises may dilute stockholders

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Spyre Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.